The West of Scotland Coronary Prevention Study (also known as WOSCOPS) was a landmark[1] randomized controlled trial, published in 1995, that investigated the effects of pravastatin, a cholesterol-lowering drug, on primary prevention of coronary heart disease (CHD) in men with hypercholesterolemia. Conducted in the early 1990s, this study provided critical evidence on the benefits of statins in reducing cardiovascular events in individuals without a history of CHD. It concluded that statin treatment reduced CHD events by 31% after nearly five years of treatment.[2]
| West of Scotland Coronary Prevention Study | |
|---|---|
| Study type | randomized controlled trial |
| Dates | enrollment February 1989 through September 1991 with 4.9 years follow-up |
| Locations | West of Scotland, Glasgow |
| Published | 1995 |
| Article | Shepherd, James; et al. (16 November 1995). "Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia". New England Journal of Medicine. 333 (20): 1301–1308. doi:10.1056/NEJM199511163332001. |
Background
editCardiovascular disease, particularly CHD, is a leading cause of death globally. High low-density lipoprotein (LDL) cholesterol levels are a well-established risk factor for developing CHD. While previous studies[3][4][5] had demonstrated the benefits of lipid-lowering agents in patients with existing CHD, the WOSCOPS was one of the first large-scale trials to evaluate the efficacy of statins for primary prevention in individuals without a prior history of cardiovascular events.[2]
Study design
editWOSCOPS was a multicenter, randomized, double-blind, placebo-controlled trial conducted in Scotland. The study enrolled 6,595 men aged 45 to 64 years (average 55 years) with elevated total cholesterol levels (average 272 mg/dl) and LDL cholesterol levels (average 192 mg/dL) and no previous history of myocardial infarction. The enrollment period was from February 1989 through September 1991. Participants were randomly assigned to receive either pravastatin (40 mg daily) or a placebo. The primary endpoint was the incidence of nonfatal myocardial infarction and death from CHD. Secondary endpoints included all-cause mortality, coronary revascularization procedures, and stroke. The patients were followed an average of 4.9 years after enrollment. Patient medical records and the national death registry were used to determine clinical results.[2][6]
Key findings
editThe results of the WOSCOPS, published in 1995,[2] demonstrated several significant benefits of pravastatin therapy for the primary prevention of CHD:
- Reduction in CHD events: Men treated with pravastatin had a 31% reduction in the risk of nonfatal myocardial infarction or death from CHD compared to those receiving the placebo.
- Decreased all-cause mortality: There was a 22% reduction in all-cause mortality in the pravastatin group.
- Fewer revascularization procedures: In the pravastatin group, the need for coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) was reduced by 37%.
- Lower incidence of stroke: Pravastatin therapy was associated with a trend towards a reduction in the incidence of stroke but was not considered statistically significant.
Clinical implications
editThe findings of the WOSCOPS had substantial implications for the prevention of CHD. This trial added to the evidence that the incidence of CHD can be reduced with statin therapy.[7] Long-term follow-up demonstrated a sustained reduction in death and coronary events.[8]
Long-term impact
editThe WOSCOPS was a pivotal trial that contributed to the broader acceptance and use of statins in the primary prevention of cardiovascular disease. Its findings have been corroborated by subsequent studies and meta-analyses, reinforcing the role of statins in reducing the risk of CHD in various populations.[9]
See also
editReferences
edit- ^ Myat, Aung; Gershlick, Anthony H., eds. (2012). Landmark Papers in Cardiovascular Medicine. Oxford University Press. p. 32. ISBN 978-0-19-959476-4.
- ^ a b c d Shepherd, James; Cobbe, Stuart M.; Ford, Ian; et al. (16 November 1995). "Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia". New England Journal of Medicine. 333 (20): 1301–1308. doi:10.1056/NEJM199511163332001.
- ^ Heady, J.A. (May 1981). "A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate: Some statistical aspects". Controlled Clinical Trials. 1 (4): 383–392. doi:10.1016/0197-2456(81)90043-X.
- ^ Rifkind, Basil M. (August 1984). "Lipid research clinics coronary primary prevention trial: Results and implications". The American Journal of Cardiology. 54 (5): 30–34. doi:10.1016/0002-9149(84)90854-3.
- ^ Frick, M. Heikki; Elo, Olli; Haapa, Kauko; et al. (12 November 1987). "Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia". New England Journal of Medicine. 317 (20): 1237–1245. doi:10.1056/NEJM198711123172001.
- ^ "A coronary primary prevention study of Scottish men aged 45-64 years: Trial design". Journal of Clinical Epidemiology. 45 (8): 849–860. August 1992. doi:10.1016/0895-4356(92)90068-x.
- ^ "West of Scotland coronary prevention study: implications for clinical practice". European Heart Journal. 17 (2): 163–164. 2 February 1996. doi:10.1093/oxfordjournals.eurheartj.a014826.
- ^ Ford, Ian; Murray, Heather; Packard, Chris J.; et al. (11 October 2007). "Long-Term Follow-up of the West of Scotland Coronary Prevention Study". New England Journal of Medicine. 357 (15): 1477–1486. doi:10.1056/NEJMoa065994.
- ^ Kashef, Mohammed Amin; Giugliano, Gregory (9 March 2017). "Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS)". Global Cardiology Science and Practice. 2016 (4). doi:10.21542/gcsp.2016.35.